The Russian Ministry of Industry and Trade introduced a new state policy for the expansion of the native pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," with the purpose to bring the Russian pharmaceutical manufacturing to a new level. This plan serves to expand the national production of innovative medications and the beginning of their massive exports abroad, principally to developing nations of Eastern Europe, Latin America and Asia-Pacific. 

The quality of domestically-manufactured medications has considerably improved in recent years, whereas the range has become more diversified according to the Russian Minister of Health Veronika Skvortsova. The production of vaccines has also been enhanced along with common drugs. Some of the global pharmaceutical companies which have running production facilities within Russia are also considered the export of medicines out of Russia. The drug trading out of Russia has become more beneficial to producers than supplies to the local market due to the devaluation of the Russian currency. Eventually, the new plan entails the generation of active substances in Russia which, successively should generate situations for the endowment of drug production, beginning from zero.